Codexis Inc at Jefferies Healthcare Conference Transcript

Jun 09, 2022 / 07:00PM GMT
Matthew Stanton -

Alright. Welcome, everyone, to the Jefferies Global Healthcare Conference. I'm Matt Stanton. I'm on the Life Science Tools and diagnostics team here at Jefferies. It's my pleasure to have Codexis back with us at the conference again this year. Joining us from the company, we have President and CEO, John Nicols, John, thanks for being here.

John J. Nicols - Codexis, Inc. - President, CEO & Director

Yes, please. Thank you.

Questions and Answers:

Matthew Stanton -

I guess to kind of kick off with a big picture question. You have the core enzyme business and the biotherapeutics pipeline. You recently started to break out segment financial performance before unallocated corporate overhead, which I think has been well received based on investor feedback. Can you just talk about how you're thinking about balancing investment in the 2 -- on one hand, you have the Performance Enzyme business, 30%-plus EBIT margins before the corporate overhead and the biotherapeutics pipeline that's consuming cash, especially in
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot